Home › Companies › RVPH

Reviva Pharmaceuticals

RVPH Rare disease Lead: Phase 3 ★ Read the deep dive → 7 Biotech Distilled articles ↓

Cardiovascular Dermatology Neurology Respiratory Small Molecule

Most recent annual filing: 2026-03-30

Pipeline (10 active programs)

brilaroxazine

RP5063

Small Molecule Target: 5-HT2A, 5-HT2B, 5-HT7, D2, D3, D4, 5-HT1A, nAChR α4β2

Schizophrenia Phase 3 oral
Bipolar Disorder oral
Major Depressive Disorder oral
Attention-Deficit/Hyperactivity Disorder oral
Behavioral and Psychotic Symptoms of Dementia oral
Parkinson's Disease Psychosis oral
Pulmonary Arterial Hypertension Preclinical
Idiopathic Pulmonary Fibrosis Preclinical
Psoriasis Preclinical

RP1208

Small Molecule Target: serotonin transporter, dopamine transporter, norepinephrine transporter

Major Depressive Disorder Preclinical

Biotech Distilled coverage (7)

2026-05-14 UPDATE: Reviva Pharmaceuticals (RVPH) - The Nasdaq Exit
2026-03-29 UPDATE: Reviva Pharmaceuticals (RVPH) - The Post-Offering Cap Table 🔒 Paid
2026-03-21 UPDATE: Reviva Pharmaceuticals (RVPH) - Reviva's $10M Dilution Spiral
2026-03-07 UPDATE: Reviva Pharmaceuticals (RVPH) - The Inevitable Arrives
2026-01-25 Update: Reviva Pharmaceuticals (RVPH) - The Cleanup Begins 🔒 Paid
2025-12-23 Update: Reviva Pharmaceuticals (RVPH) – The Bear Case is Here – FDA Requires Second Phase 3 Trial
2025-12-15 Scientific Due Diligence for Brilaroxazine: Reviva Pharmaceuticals (RVPH)

Articles open on Substack. Some deep dives are subscriber-only.